The randomized, phase 3 BEACON CRC trial was a 3-arm study conducted in patients with pretreated metastatic CRC characterized by a BRAF V600E mutation.
Synchronous metastatic disease is characterized by the presence of metastatic lesions, in addition to the primary tumor, at diagnosis.
Even though older adults were prescribed second-line therapies less frequently than younger adults, patients had similar overall survival outcomes across age subgroups.
In this study, a young adult was defined as an individual who was 40 years or younger.
Even after adjustment for tumor stage, patients with ulcerative colitis have higher risk for CRC mortality.
The decision to adopt bevacizumab could be appraised by the prior level of uptake among their peers in their medical community.
After colorectal cancer screening guidelines lowered the age at which to start screening to age 45 years, increased screening rates followed among younger individuals.
Without a “clear” overall survival benefit from maintenance therapy, observation remains an option for patients with metastatic colorectal cancer.
NCI-MATCH trial identified additional patients who may benefit from nivolumab.
Increase in screening rates in quarters 3, 4 of 2018 versus quarter 1; no change for people in their 50s
